Condition
X-ALD
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.3% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Terminated2
Recruiting1
Withdrawn1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05394064Phase 1Terminated
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
NCT02699190Completed
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT05008874Terminated
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
NCT03047369Recruiting
The Myelin Disorders Biorepository Project
NCT03649919Withdrawn
Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children
Showing all 5 trials